CLDX vs MYGN
Celldex Therapeutics, Inc. and Myriad Genetics Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | CLDX | MYGN |
|---|---|---|
| Revenue | $1.5M | $824.5M |
| Net income | $-258.8M | $-365.9M |
| Gross margin | 87.1% | 69.9% |
| Net margin | · | −44.4% |
| Return on equity | −40.6% | −68.5% |
| Diluted EPS | −$3.90 | −$3.95 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $-213.7M | · |
| Equity | $527.2M | $368.0M |
| Net debt / equity | · | −0.08× |
| Current ratio | 10.49× | 2.49× |
| Revenue CAGR 5y | −26.9% | 8.2% |
| Profit CAGR 5y | · | · |
MYGN bills 533.7× the revenue of CLDX, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | CLDX | MYGN |
|---|---|---|
| FY2025 | $1.5M | $824.5M |
| FY2024 | $7.0M | $837.6M |
| FY2023 | $6.9M | $753.2M |
| FY2022 | $2.4M | $678.4M |
| FY2021 | $4.7M | $690.6M |
| FY2020 | $7.4M | $557.1M |
| FY2019 | $3.6M | $638.6M |
| FY2018 | $9.5M | $851.1M |
| FY2017 | $12.7M | $743.7M |
| FY2016 | $6.8M | $728.7M |
Bottom line
| Fiscal year | CLDX | MYGN |
|---|---|---|
| FY2025 | $-258.8M | $-365.9M |
| FY2024 | $-157.9M | $-127.3M |
| FY2023 | $-141.4M | $-263.3M |
| FY2022 | $-112.3M | $-112.0M |
| FY2021 | $-70.5M | $-27.2M |
| FY2020 | $-59.8M | $-223.6M |
| FY2019 | $-50.9M | $-199.5M |
| FY2018 | $-151.2M | $4.6M |
| FY2017 | $-93.0M | $133.3M |
| FY2016 | $-128.5M | $17.4M |
17 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$822,955,000 | MYGN |
| FY2024 | −$830,580,000 | MYGN |
| FY2023 | −$746,317,000 | MYGN |
| FY2022 | −$676,043,000 | MYGN |
| FY2021 | −$685,949,000 | MYGN |
| FY2020 | −$549,682,000 | MYGN |
| FY2019 | −$635,027,000 | MYGN |
| FY2018 | −$841,562,000 | MYGN |
| FY2017 | −$730,957,000 | MYGN |
| FY2016 | −$721,914,000 | MYGN |
| FY2015 | −$735,020,000 | MYGN |
| FY2014 | −$718,914,000 | MYGN |
| FY2013 | −$774,089,000 | MYGN |
| FY2012 | −$601,998,000 | MYGN |
| FY2011 | −$486,740,000 | MYGN |
| FY2010 | −$355,291,000 | MYGN |
| FY2009 | −$347,468,000 | MYGN |
MYGN has reported the higher revenue in every one of these 17 fiscal years. The gap has widened since the earliest year compared.
17 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MYGN's return on equity has been more volatile than CLDX's over the 17 comparable fiscal years — 24.8 percentage points of standard deviation against 18.0.
17 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between CLDX and MYGN over these 17 fiscal years — CLDX led in 1 and MYGN in 16.
17 of 18 comparable fiscal years — a year missing data on either side is not counted.